Accumulating studies explored the clinicopathologic and prognostic value of programmed death ligand-1(PD-L1) in non-small cell lung cancer(NSCLC), but the results were controversial. We therefore conducted a meta-...Accumulating studies explored the clinicopathologic and prognostic value of programmed death ligand-1(PD-L1) in non-small cell lung cancer(NSCLC), but the results were controversial. We therefore conducted a meta-analysis to evaluate the predictive role of PD-L1 in NSCLC patients. We systematically collected relevant studies from Pub Med, Embase, Web of Science and China National Knowledge Infrastructure. The pooled hazard ratios(HRs) with 95% confidence intervals(CIs) for overall survival(OS), and odd ratios(ORs) with 95% CIs for clinicopathologic factors were calculated. A total of 15 studies involving 3605 patients were included in this meta-analysis. The results showed no prognostic role of PD-L1 in the whole patients(HR=1.60, 95% CI: 0.88–2.89, P=0.123). Subgroup analysis showed that PD-L1 was associated with decreased OS in Asian patients(HR=2.00, 95% CI: 1.55–2.57, P〈0.001). Among all the clinicopathologic factors, PD-L1 overexpression was significantly in relevance with poor tumor cell differentiation(HR=1.84, 95% CI: 1.49–2.28, P〈0.001), late stage(HR=1.21, 95% CI: 1.02–1.43, P=0.026) and anaplastic lymphoma kinase(ALK) translocation(HR=2.63, 95% CI: 1.08–6.40, P=0.034), but not with other factors. In conclusion, our meta-analysis demonstrated that PD-L1 has a prognostic role in Asian patients with NSCLC.展开更多
Lung cancer is the leading cause of cancerrelated mortality in China.(1'2) Meanwhile, the average life expectancy in the aging population has increased from 46 years in 1950 to 75 years in 2010.
Non-small cell lung cancer (NSCLC) is the leading cause of cancer death in the industrialized world. Despite significant progress in early stage of the disease, the overall survival rates for advanced disease remain...Non-small cell lung cancer (NSCLC) is the leading cause of cancer death in the industrialized world. Despite significant progress in early stage of the disease, the overall survival rates for advanced disease remain low. Herein we present a case of NSCLC who was treated with Chinese medicine and chemotherapy with a longer overall survival.展开更多
基金supported by National Natural Science Foundation of China(No.81372260)
文摘Accumulating studies explored the clinicopathologic and prognostic value of programmed death ligand-1(PD-L1) in non-small cell lung cancer(NSCLC), but the results were controversial. We therefore conducted a meta-analysis to evaluate the predictive role of PD-L1 in NSCLC patients. We systematically collected relevant studies from Pub Med, Embase, Web of Science and China National Knowledge Infrastructure. The pooled hazard ratios(HRs) with 95% confidence intervals(CIs) for overall survival(OS), and odd ratios(ORs) with 95% CIs for clinicopathologic factors were calculated. A total of 15 studies involving 3605 patients were included in this meta-analysis. The results showed no prognostic role of PD-L1 in the whole patients(HR=1.60, 95% CI: 0.88–2.89, P=0.123). Subgroup analysis showed that PD-L1 was associated with decreased OS in Asian patients(HR=2.00, 95% CI: 1.55–2.57, P〈0.001). Among all the clinicopathologic factors, PD-L1 overexpression was significantly in relevance with poor tumor cell differentiation(HR=1.84, 95% CI: 1.49–2.28, P〈0.001), late stage(HR=1.21, 95% CI: 1.02–1.43, P=0.026) and anaplastic lymphoma kinase(ALK) translocation(HR=2.63, 95% CI: 1.08–6.40, P=0.034), but not with other factors. In conclusion, our meta-analysis demonstrated that PD-L1 has a prognostic role in Asian patients with NSCLC.
基金Supported by the National Natural Science Foundation of China(No.81273718 and No.81102719)
文摘Lung cancer is the leading cause of cancerrelated mortality in China.(1'2) Meanwhile, the average life expectancy in the aging population has increased from 46 years in 1950 to 75 years in 2010.
文摘Non-small cell lung cancer (NSCLC) is the leading cause of cancer death in the industrialized world. Despite significant progress in early stage of the disease, the overall survival rates for advanced disease remain low. Herein we present a case of NSCLC who was treated with Chinese medicine and chemotherapy with a longer overall survival.